TriLink, Aldevron enter into license and supply pact for CleanCap

TriLink BioTechnologies, a Maravai LifeSciences (MRVI) company and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap mRNA capping technologies to those developing critical mRNA-based therapeutics and vaccines. According to the terms of the agreement, TriLink will supply its patented CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, and CleanCap AU cap analogs for use in Aldevron’s mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap technology produces optimal 5’Cap structures with over 95% efficiency, creating a co-transcriptional capping solution that improves mRNA yield and process time when compared to legacy capping methods. “CleanCap technology is accelerating programs through drug development milestones and has been the capping technology of choice for mRNA constructs in 350+ preclinical and clinical programs,” shared Becky Buzzeo, Chief Commercial Officer, Maravai. “We’re excited to offer our innovative capping solutions to Aldevron and its manufacturing customers.”